Vertex goes back to gene-editing partner — and science founder Feng Zhang — to add $1.2B deal on engineered cell therapies
Close to 3 years after Vertex helped Arbor Biotechnologies get off the ground with a reputation-building alliance to build gene-editing tools for a suite of core diseases, including cystic fibrosis, they’ve come back to go up to $1.2 billion deeper into their shared journey of discovery. Only this time they’re collaborating on ex vivo engineered cell therapies.
They’ve broadened the sphere of their work with the biotech, going after type 1 diabetes as well as sickle cell disease and beta thalassemia — plus a few that are being left off the radar for now.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.